Anima Cell Metrology seeks to raise $6m in Tel Aviv

Poalim IBI Underwriting and Investments will lead the offering.

Anima Cell Metrology Ltd. has published a draft prospectus for an IPO on the Tel Aviv Stock Exchange (TASE). The company seeks to raise $6 million at a company value of $15 million.

Poalim IBI Underwriting and Investments Ltd. (TASE:PIU) will lead the offering.

Anima Cell Metrology was founded by Zeev Smilanksy, a biologist, vintner, and son of the author S. Yizhar; and Dr. Michal Preminger, who previously served as business development manager at Lucent Technologies and Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) and is currently an executive director at Harvard Office of Technology Development.

Anima CEO Roni Appel previously served as CEO of Advaxis Inc. (Bulletin Board: ADXS), which develops cancer vaccines.

Anima has developed a method for testing the activity of proteins in real time, compared with the current method, in which the protein is first destroyed and then analyzed in order to figure out its activity in retrospect. The company's main target market is research laboratories.

The draft prospectus states that Anima does not yet have sales, and that it has lost hundreds of thousands of dollars a year in recent years. The company has raised a few hundred thousand dollars to date, and received a $2 million NIST Advanced Technology Program research grant. The company plans to obtain more research grants in the future.

A group comprising Smilansky, Preminger, and private investors owns 71% of Anima. Other investors included former Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) director Harold Snyder, the LEVP Fund managed by Appel, and angel investors Max Herzberg, Prof. Shmuel Kabili, and Hezi Bernholz.

Published by Globes [online], Israel business news - www.globes-online.com - on October 14, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters